930 WINTER STREET, WALTHAM, MA
License Agreement with Paragon Therapeutics - Jade Biosciences, Inc.
Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Amendment to Articles of Incorporation Approved at 2026 Annual Meeting
Announces Pricing of Public Offering of Common Stock
Reg. FD, Other Events
Annual Report to Security Holders
Andrew King Appointed President, Research & Development at Jade Biosciences
Jade Biosciences Approves 2026 Employment Inducement Stock Plan
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership